Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol’s drug, Camzyos, failed in a heart disease study.

The post Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It appeared first on Investor’s Business Daily.